We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Zevra Therapeutics is a rare disease company melding science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. Zevra Therapeutics, formerly known as KemPharm Inc., is based in CELEBRATION, Fla.
- Recent ZVRA Stock Price: $5.03
- Yearly Gain for ZVRA stock: -9.37%
- Market Cap for ZVRA stock: $208.67M
- P/E Ratio for ZVRA stock: -4.34
Will ZVRA's stock price go up? Is there an accurate ZVRA stock forecast available?
TipRanks.com reports that Zevra Therapeutics, Inc. currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $19.33. The target pricing ranges from a high ZVRA forecast of $24 down to a low forecast of $15. Zevra Therapeutics, Inc. (ZVRA)’s last closing stock price was $5.03 which would put the average price target at 284.36% upside.
In addition, TradingView issued a rating for ZVRA stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ZVRA stock.
Other analysts covering ZVRA include:
- Jonathan Aschoff of Roth MKM issued a Buy rating with the price target of $19 on 2 days ago
- Sumant Kulkarni of Canaccord Genuity issued a Buy rating with the price target of $24 on 1 week ago
If you are wondering if ZVRA is a good stock to buy, here are 3rd party ratings for ZVRA stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Top 37% (93 out of 252)
What is the sentiment on the street regarding Zevra Therapeutics, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ZVRA stock: Bullish
- Blogger Consensus for ZVRA stock:
- Media Buzz for ZVRA stock: Neutral
- Insider Signal for ZVRA stock: Selling
- Investor Sentiment for ZVRA stock: Positive
- Hedge Fund signal for ZVRA stock: High Risk
The stock market is extremely volatile, and you need to do your own research on ZVRA stock including scouring the social networks like ZVRA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ZVRA stock chart >>
Summary: atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
- Recent ATAI Stock Price: $2.39
- Yearly Gain for ATAI stock: 25.79%
- Market Cap for ATAI stock: $396.80M
- P/E Ratio for ATAI stock: -5.56
Will ATAI's stock price go up? Is there an accurate ATAI stock forecast available?
TipRanks.com reports that Atai Life Sciences N.V. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.75. The target pricing ranges from a high ATAI forecast of $6 down to a low forecast of $11. Atai Life Sciences N.V. (ATAI)’s last closing stock price was $2.39 which would put the average price target at 349.79% upside.
In addition, TradingView issued a rating for ATAI stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ATAI stock.
Other analysts covering ATAI include:
- Patrick Trucchio of H.C. Wainwright issued a Buy rating with the price target of $15 on 18 hours ago
- Michael Okunewitch of Maxim Group issued a Buy rating with the price target of $6 on 18 hours ago
- Caroline Palomeque of Berenberg Bank issued a Buy rating with the price target of $11 on 7 months ago
If you are wondering if ATAI is a good stock to buy, here are 3rd party ratings for ATAI stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 34% (86 out of 252)
What is the sentiment on the street regarding Atai Life Sciences N.V.? (Current ratings compiled by TipRanks.com)
- News Sentiment for ATAI stock: Bullish
- Blogger Consensus for ATAI stock:
- Media Buzz for ATAI stock: Neutral
- Insider Signal for ATAI stock: Buying
- Investor Sentiment for ATAI stock: Positive
- Hedge Fund signal for ATAI stock: High Risk
The stock market is extremely volatile, and you need to do your own research on ATAI stock including scouring the social networks like ATAI StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ATAI stock chart >>
Summary: Baxter International Inc. is a global medical technology company. The company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions. Baxter has been reporting through six revenue segments. Renal Care, Medication Delivery, Pharmaceuticals, Clinical Nutrition, Advanced Surgery, Acute Therapies and Other. Baxter's Renal segment primarily consists of Peritoneal Dialysis (PD) and Hemodialysis (HD) therapies. The portfolio addresses the needs of patients with kidney failure or kidney disease, and their healthcare providers, with a comprehensive range of therapeutic options across home, in-center, and hospital settings for better individualized care.
- Recent BAX Stock Price: $43.28
- Yearly Gain for BAX stock: 8.25%
- Market Cap for BAX stock: $21.99B
- P/E Ratio for BAX stock: -288.53
Will BAX's stock price go up? Is there an accurate BAX stock forecast available?
TipRanks.com reports that Baxter International Inc. currently has 5 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $46.20. The target pricing ranges from a high BAX forecast of $54 down to a low forecast of $44. Baxter International Inc. (BAX)’s last closing stock price was $43.28 which would put the average price target at 6.75% upside.
In addition, TradingView issued a rating for BAX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on BAX stock.
Other analysts covering BAX include:
- Matt Miksic of Barclays issued a Buy rating with the price target of $54 on 1 day ago
- Larry Biegelsen of Wells Fargo issued a Hold rating with the price target of $44 on 2 days ago
- Travis Steed of Bank of America Securities issued a Hold rating with the price target of $45 on 4 weeks ago
- Robbie Marcus of J.P. Morgan issued a Hold rating with the price target of $44 on 1 month ago
If you are wondering if BAX is a good stock to buy, here are 3rd party ratings for BAX stock:
- TipRanks.com: Hold
- TradingView.com:
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 38% (95 out of 252)
What is the sentiment on the street regarding Baxter International Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for BAX stock: Bullish
- Blogger Consensus for BAX stock:
- Media Buzz for BAX stock: Strong Buy
- Insider Signal for BAX stock: Balanced
- Investor Sentiment for BAX stock: Positive
- Hedge Fund signal for BAX stock: Medium Risk
The stock market is extremely volatile, and you need to do your own research on BAX stock including scouring the social networks like BAX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BAX stock chart >>
Summary: OPKO Health, Inc engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel and Mexico. The Diagnostics segment operates Bio-Reference Laboratories, a clinical facility that offers testing services in the detection, diagnosis, evaluation, monitoring and treatment of diseases. The company's pharmaceutical business features Rayaldee, an FDA-approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy induced nausea and vomiting. OPKO Health has a development and commercial supply pharmaceutical unit in Ireland along with a global supply chain operation and holding wing. The company also owns specialty active pharmaceutical ingredients (APIs) manufacturer in Israel.
- Recent OPK Stock Price: $1.35
- Yearly Gain for OPK stock: -12.34%
- Market Cap for OPK stock: $940.94M
- P/E Ratio for OPK stock: -5.4
Will OPK's stock price go up? Is there an accurate OPK stock forecast available?
TipRanks.com reports that OPKO Health, Inc. currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $3.63. The target pricing ranges from a high OPK forecast of $5 down to a low forecast of $1.5. OPKO Health, Inc. (OPK)’s last closing stock price was $1.35 which would put the average price target at 168.52% upside.
In addition, TradingView issued a rating for OPK stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on OPK stock.
Other analysts covering OPK include:
- Michael Petusky of Barrington issued a Buy rating with the price target of $1.5 on 2 days ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $5 on 2 days ago
- Jeffrey Cohen of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $5 on 4 months ago
If you are wondering if OPK is a good stock to buy, here are 3rd party ratings for OPK stock:
- TipRanks.com: Buy
- TradingView.com:
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Sell, Top 25% (64 out of 252)
What is the sentiment on the street regarding OPKO Health, Inc.? (Current ratings compiled by TipRanks.com)
- News Sentiment for OPK stock: Bullish
- Blogger Consensus for OPK stock:
- Media Buzz for OPK stock: Neutral
- Insider Signal for OPK stock: Buying
- Investor Sentiment for OPK stock: Negative
- Hedge Fund signal for OPK stock: High Risk
The stock market is extremely volatile, and you need to do your own research on OPK stock including scouring the social networks like OPK StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for OPK stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================